34097-37-5 Usage
Description
N,N'-1H-PURINE-2,6-DIYBIS ACETAMIDE is a purine derivative featuring two acetamide groups attached to the 2 and 6 positions of the purine ring. It is a chemical compound that plays a role in DNA and RNA structure and is involved in various biochemical processes within the body. N,N'-1H-PURINE-2,6-DIYBIS ACETAMIDE may have potential applications in the pharmaceutical industry, particularly in the development of drugs that target purine metabolism or related pathways.
Uses
Used in Pharmaceutical Industry:
N,N'-1H-PURINE-2,6-DIYBIS ACETAMIDE is used as a potential drug candidate for targeting purine metabolism or related pathways. Its unique structure and interaction with biochemical processes make it a promising compound for the development of new therapeutic agents.
Proper handling and storage protocols should be followed to ensure the safety and efficacy of N,N'-1H-PURINE-2,6-DIYBIS ACETAMIDE in its intended applications.
Check Digit Verification of cas no
The CAS Registry Mumber 34097-37-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,4,0,9 and 7 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 34097-37:
(7*3)+(6*4)+(5*0)+(4*9)+(3*7)+(2*3)+(1*7)=115
115 % 10 = 5
So 34097-37-5 is a valid CAS Registry Number.
34097-37-5Relevant articles and documents
Prolinamides of Aminouracils, Organocatalyst Modifiable by Complementary Modules
Ruíz-Pérez, Karen M.,Quiroz-García, Beatriz,Hernández-Rodríguez, Marcos
supporting information, p. 5763 - 5772 (2018/11/10)
We report the synthesis and evaluation of prolinamide organocatalysts that incorporate aminouracils. The features of these catalysts are enhanced NH acidity of the amide because of the electron-withdrawing nature of the heterocycle, an additional hydrogen-bond donor at the α or β positions of this functional group (using 6-aminouracil or 5,6-diaminouracil respectively), and it can be recovered due to its low solubility and used again without decreasing the enantioselectivity. A unique feature of these systems is the self-assembly capability with complementary modules by Watson–Crick interactions. These supramolecular adducts behave differently from the catalyst alone, some of them have lower performance but others improve the selectivity of the product. Therefore, this approach avoids the synthesis of many catalysts.